Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson reports ‘effective’ treatment for diabetic foot infections

Johnson and Johnson reports ‘effective’ treatment for diabetic foot infections

9th October 2007

Johnson & Johnson Pharmaceutical Research & Development, a segment of Johnson & Johnson, has announced the results of a phase III clinical trial showing that the antibiotic ceftobiprole is effective as a combination treatment for patients with diabetic foot infections.

The trial results, presented to the annual meeting of the Infectious Disease Society of America in San Diego, showed that the drug clinically cured 86 per cent of patients with the condition, including those with infections caused by methicillin-resistant Staphylococcus aureus.

Johnson & Johnson is licensing the compound from Basilea Pharmaceutica, its co-development partner for the drug, which was administered intravenously together with timed injections of conjunction with vancomycin and ceftazidime.

Gary J Noel, franchise medical leader for anti-infectives at Johnson & Johnson Pharmaceutical Research & Development, said: “These data suggest that ceftobiprole may be useful as stand-alone therapy for this increasingly common type of complicated skin infection.”

He added that diabetic foot infections are becoming an increasingly difficult condition to treat.

In August 2007, Janssen-Cilag, a Johnson & Johnson company, submitted a marketing authorisation application with regulators in Switzerland for the approval of ceftobiprole as a treatment for complicated skin and soft tissue infections, including diabetic foot infections.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.